Systemic and intrahepatic interferon‐gamma‐inducible protein 10 kDa predicts the first‐phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C
Galia Askarieh, Åsa Alsiö, Paolo Pugnale, Francesco Negro, Carlo Ferrari, Avidan U. Neumann, Jean‐Michel Pawlotsky, Solko W. Schalm, Stefan Zeuzem, Gunnar Norkrans, Johan Westin, Jonas Söderholm, Kristoffer Hellstrand, Martin Lagging, DITTO‐HCV and NORDynamIC Study Groups – 22 April 2010 – High systemic levels of interferon‐gamma‐inducible protein 10 kDa (IP‐10) at onset of combination therapy for chronic hepatitis C virus (HCV) infection predict poor outcome, but details regarding the impact of IP‐10 on the reduction of HCV RNA during therapy remain unclear.